PMID- 30449785
OWN - NLM
STAT- MEDLINE
DCOM- 20190503
LR  - 20200225
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Print)
IS  - 0918-2918 (Linking)
VI  - 58
IP  - 6
DP  - 2019 Mar 15
TI  - Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following 
      High-dose (3 g/kg) Intravenous Immunoglobulin Therapy.
PG  - 855-859
LID - 10.2169/internalmedicine.1723-18 [doi]
AB  - We report the case of a 53-year-old woman with severe chronic inflammatory 
      demyelinating polyneuropathy (CIDP) who developed progressive tetraplegia with 
      respiratory failure despite receiving a standard dose of intravenous 
      immunoglobulin therapy (IVIg), steroid pulse therapy, plasma exchange, and 
      cyclosporine. We administered high-dose IVIg (3 g/kg; 0.6 g/kg/day for 5 
      consecutive days at monthly intervals). The patient's muscle weakness gradually 
      improved after IVIg. She recovered completely 2 years after the onset of 
      symptoms. The effects of IVIg treatment in individuals with CIDP may vary in each 
      patient. In patients with refractory CIDP receiving standard-dose IVIg, repeated 
      high-dose IVIg treatment can be considered.
FAU - Seino, Yusuke
AU  - Seino Y
AD  - Department of Neurology, Hirosaki University Graduate School of Medicine, Japan.
FAU - Nakamura, Takumi
AU  - Nakamura T
AD  - Department of Neurology, Hirosaki University Graduate School of Medicine, Japan.
FAU - Hirohata, Mie
AU  - Hirohata M
AD  - Department of Neurology, Hirosaki University Graduate School of Medicine, Japan.
FAU - Kawarabayashi, Takeshi
AU  - Kawarabayashi T
AD  - Department of Neurology, Hirosaki University Graduate School of Medicine, Japan.
FAU - Okushima, Toshimi
AU  - Okushima T
AD  - Department of Neurology, Hachinohe City Hospital, Japan.
FAU - Shoji, Mikio
AU  - Shoji M
AD  - Department of Neurology, Hirosaki University Graduate School of Medicine, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20181119
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Immunologic Factors/*therapeutic use
MH  - Middle Aged
MH  - Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/*drug therapy
MH  - Severity of Illness Index
PMC - PMC6465009
OTO - NOTNLM
OT  - chronic inflammatory demyelinating polyneuropathy (CIDP)
OT  - high-dose intravenous immunoglobulin therapy (IVIg)
OT  - pentaplegia
OT  - respiratory failure
COIS- The authors state that they have no Conflict of Interest (COI).
EDAT- 2018/11/20 06:00
MHDA- 2019/05/06 06:00
PMCR- 2019/03/15
CRDT- 2018/11/20 06:00
PHST- 2018/11/20 06:00 [pubmed]
PHST- 2019/05/06 06:00 [medline]
PHST- 2018/11/20 06:00 [entrez]
PHST- 2019/03/15 00:00 [pmc-release]
AID - 10.2169/internalmedicine.1723-18 [doi]
PST - ppublish
SO  - Intern Med. 2019 Mar 15;58(6):855-859. doi: 10.2169/internalmedicine.1723-18. 
      Epub 2018 Nov 19.